CALCA calcitonin related polypeptide alpha
ENSG00000110680 · protein coding · Open Targets profile
[Calcitonin]: Calcitonin is a peptide hormone that causes a rapid but short-lived drop in the level of calcium and phosphate in blood by promoting the incorporation of those ions in the bones. Calcitonin function is mediated by the calcitonin receptor/CALCR and the CALCR-RAMP2 (AMYR2) receptor complex (PubMed:35324283). .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
gnomAD loss of function constraint: o/e 0.580079972743988 (upper bound 1.3273999691009521). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 37 registry trials, updated in the last three years, of the most advanced drugs against CALCA (eptinezumab, galcanezumab, fremanezumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Angel L Guerrero PeralSanidad de Castilla y León · 1 of 1 trials Phase 2+
- Carolyn A BernsteinBrigham and Women's · 1 of 1 trials Phase 2+
- Charles ArgoffAlbany Medical College · 1 of 1 trials Phase 2+
- Howard MengSunnybrook Health Sciences Centre · 1 of 1 trials Phase 2+
- Jeffrey D SharonUniversity of California, San Francisco · 1 of 1 trials Phase 2+
- Kristen K. SteenersonStanford University · 1 of 1 trials Phase 2+
- Lisa C RoseneggerAlberta Neurologic Centre · 1 of 1 trials Phase 2+
- Matthew FitzgeraldStanford University · 1 of 1 trials Phase 2+
- Narayan KissoonMayo Clinic · 1 of 1 trials Phase 2+
- Rami BursteinBeth Israel Deaconess Medical Center · 1 of 1 trials Phase 2+
- Rigmor H JensenDanish Headache Center · 1 of 1 trials Phase 2+
- Sait AshinaBeth Israel Deaconess Medical Center · 1 of 1 trials Phase 2+
- Sweta SenguptaDuke University · 1 of 1 trials Phase 2+
- Katherine HutchesonUT MD Anderson · 0 of 1 trials Phase 2+
- Lene VaseDept. of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark · 0 of 1 trials Phase 2+
Registry trials of eptinezumab, galcanezumab, fremanezumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 21 of 34 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 3 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
11 trials of drugs against CALCA were stopped early
Terminated, withdrawn and suspended interventional trials of eptinezumab, galcanezumab, fremanezumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 11 most recent of 11.
- terminated · 2026-02-27 · Beth Israel Deaconess Medical Center · Fremanezumab Prefilled Syringe [Ajovy]“poor enrollment”
- withdrawn · 2025-03-06 · Mayo Clinic · Eptinezumab“no participants enrolled”
- terminated · 2024-05-29 · H. Lundbeck A/S · Eptinezumab, Fremanezumab, Galcanezumab“The study was terminated due to enrolment challenges.”
- terminated · 2023-09-29 · Diamond Headache Clinic · Galcanezumab“Stopped from financial sponsor due to inability to enroll participants.”
- terminated · 2023-03-30 · Teva Branded Pharmaceutical Products R&D, Inc. · Fremanezumab“Met pre-specified criteria for futility at interim analysis”
- withdrawn · 2022-02-28 · Mayo Clinic · Fremanezumab“Lack of funding to support the trial.”
- terminated · 2021-11-09 · Teva Branded Pharmaceutical Products R&D, Inc. · Fremanezumab“Study was terminated as a result of a pre-specified futility analysis at the interim of 150 participants completing the efficacy analysis of the study.”
- terminated · 2021-11-09 · Teva Branded Pharmaceutical Products R&D, Inc. · Fremanezumab“The study was terminated after the episodic cluster study was terminated due to a pre specified futility analyses”
- withdrawn · 2021-11-09 · Teva Branded Pharmaceutical Products R&D, Inc. · fremanezumab“Withdrawn due to logistic reasons”
- terminated · 2021-11-09 · Teva Branded Pharmaceutical Products R&D, Inc. · Fremanezumab“Futility analysis revealed that the primary endpoint is unlikely to be met. There were no safety concerns observed with fremanezumab treatment in the trial.”
- terminated · 2019-09-10 · Eli Lilly and Company · matched by the registry's drug synonyms“Interim assessment: Lack of efficacy”
Paediatric incentives and obligations for CALCA's drugs
For eptinezumab, galcanezumab, fremanezumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · CALCA is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000227737 (Galcanezumab, Prevention of migraine headaches): PM: decision on the application for modification of an agreed PIP, 12 Jun 2025; EMA/PE/0000223490 (Eptinezumab, Prevention of migraine headaches): PM: decision on the application for modification of an agreed PIP, 28 Jan 2025; EMEA-001877-PIP01-15-M04 (fremanezumab, Prevention of migraine headaches): PM: decision on the application for modification of an agreed PIP, 8 Sept 2023; EMEA-002243-PIP02-20 (Eptinezumab, Prevention of cluster headaches): W: decision granting a waiver in all age groups for all conditions or indications, 17 Mar 2021; compliance positive 20 Sept 2019; +2 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names eptinezumab, galcanezumab, fremanezumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Vyepti: authorised since 24 Jan 2022; Emgality: authorised since 14 Nov 2018; Ajovy: authorised since 28 Mar 2019Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of eptinezumab, galcanezumab, fremanezumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 9 interventional studies of eptinezumab, galcanezumab, fremanezumab include patients under 18; 5 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 3 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.